Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS). (Q30976008)

27 June 2017

title

Vaccination of persons allergic to latex: a review of safety data in the Vaccine Adverse Event Reporting System (VAERS). (English)

1 reference

Vaccine Adverse Event Reporting System

27 June 2017

main subject

1 reference

based on heuristic

inferred from title

vaccine adverse event

1 reference

Michelle Russell

1

1 reference

27 June 2017

Vitali Pool

series ordinal

2

1 reference

27 June 2017

John M Kelso

series ordinal

3

1 reference

27 June 2017

Vesna J Tomazic-Jezic

series ordinal

4

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

27 June 2017

number of pages

4

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

27 June 2017

volume

23

1 reference

27 June 2017

issue

5

1 reference

27 June 2017

page(s)

664-667

1 reference

The Vaccine Adverse Event Reporting System (VAERS)

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

Natural rubber pharmaceutical vial closures release latex allergens that produce skin reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

Risk of latex allergy from medication vial closures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

Lack of latex allergen contamination of solutions withdrawn from vials with natural rubber stoppers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

Latex allergy in diabetic patients: a call for latex-free insulin tops

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

Local Reaction Secondary to Insulin Injection: A potential role for latex antigens in insulin vials and syringes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

Anaphylaxis after hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

Risk of Anaphylaxis After Vaccination of Children and Adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

Latex sensitization: occupational versus general population prevalence rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

The prevalence of anti-latex IgE antibodies in 1000 volunteer blood donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

Natural rubber latex sensitivity seminar: conference summary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

Monitoring the safety of vaccines: assessing the risks

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. VAERS Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

Enhancing vaccine safety surveillance: a capture-recapture analysis of intussusception after rotavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2004.06.042

10.1016/J.VACCINE.2004.06.042

7 January 2021

Identifiers

DOI

1 reference

27 June 2017

1 reference